Concentration–QTc analysis of quizartinib in patients with relapsed/refractory acute myeloid leukemia
Sign Up to like & getrecommendations! Published in 2021 at "Cancer Chemotherapy and Pharmacology"
DOI: 10.1007/s00280-020-04204-y
Abstract: This analysis evaluated the relationship between concentrations of quizartinib and its active metabolite AC886 and QT interval corrected using Fridericia’s formula (QTcF) in patients with relapsed/refractory acute myeloid leukemia (AML) treated in the phase 3… read more here.
Keywords: relapsed refractory; qtcf; analysis; quizartinib ... See more keywords
Exposure-Response of Quizartinib Efficacy in Patients with Relapsed/Refractory AML
Sign Up to like & getrecommendations! Published in 2019 at "Blood"
DOI: 10.1182/blood-2019-122582
Abstract: Introduction: Quizartinib is a once-daily, oral, highly potent and selective FLT3 inhibitor that has shown clinical activity in patients with relapsed/refractory acute myeloid leukemia (AML) with FLT3 internal tandem duplications in the phase 3 QuANTUM-R… read more here.
Keywords: exposure response; analysis; quizartinib; exposure ... See more keywords